Diary - News
All news Adocia and Lilly announce completion of an insulin pump study
Adocia (Euronext Paris: ADOC) and Eli Lilly and Company (NYSE: LLY) announced successful completion of an insulin pump study under the Adocia-Lilly partnership evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia’s proprietary technology BioChaperone®, designed to accelerate insulin absorption.
